bioLytical™ Laboratories Initiates Patient Enrollment in New Trial for INSTI(TM), 60-Second Rapid HIV Test

Published: Jul 31, 2007

VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Jul 31, 2007 -- bioLytical Laboratories (bioLytical) today announced the first 25 patients have been enrolled in their Investigational Device Exemption (IDE) study for approval by the U.S. Food and Drug Administration (FDA) of INSTI(TM), a 60-second rapid HIV test for point-of-care (POC) testing. bioLytical's IDE filing was accepted by the FDA July 6, 2007.

Back to news